Market Lens IQ is a global market intelligence and strategic consulting firm delivering advanced syndicated research reports, customized industry analysis, competitive intelligence, and data-driven advisory solutions to organizations across international markets. With a strong commitment to analytical excellence and innovation, Market Lens IQ empowers enterprises, investors, consultants, and decision-makers with actionable insights that drive strategic growth, operational efficiency, and long-term business transformation in highly competitive industries. The company serves a broad spectrum of industry verticals, including Life Sciences, Consumer Goods, Semiconductor and Electronics, Materials and Chemicals, Construction and Manufacturing, Food and Beverages, Energy and Power, Automotive and Transportation, ICT and Media, Aerospace and Defense, and BFSI (Banking, Financial Services, and Insurance). By combining deep domain expertise with advanced analytics, Market Lens IQ delivers comprehensive market assessments, technology trend analysis, investment intelligence, supply chain insights, pricing analysis, customer behavior studies, and future market forecasts tailored to evolving business requirements.
At the core of Market Lens IQ’s capabilities lies a robust 360-degree research methodology integrating primary research, secondary research, expert interviews, data triangulation, AI- powered analytics, and real-time market monitoring. Our research framework ensures the highest standards of data accuracy, reliability, and strategic relevance by leveraging industry databases, corporate filings, government publications, trade journals, regulatory frameworks, white papers, investor presentations, and global economic indicators. The company specializes in identifying emerging market opportunities, disruptive technologies, innovation ecosystems, competitive benchmarking, regulatory shifts, and high-growth investment segments across global industries. Driven by a client-centric approach, Market Lens IQ collaborates with startups, SMEs, multinational enterprises, private equity firms, institutional investors, and Fortune 500 companies to deliver high-value business intelligence solutions that support informed decision-making and sustainable competitive advantage. Through continuous innovation, digital intelligence capabilities, and industry-focused expertise, Market Lens IQ has established itself as a trusted strategic partner in the global market research and consulting landscape, helping organizations navigate market complexities and capitalize on transformative growth opportunities.
In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
North America Psoriasis Therapeutics Market Size & Forecast 2032
North America psoriasis therapeutics Market
North America Psoriasis Therapeutics Market Size & Forecast 2032
North America psoriasis therapeutics Market by Drug Class (TNF-alpha Inhibitors, Interleukin Inhibitors, Others), by Type (Plaque Psoriasis, Psoriatic Arthritis, Others), by Route of Administration (Oral, Parenteral, Topical), by North America (USA, Canada, Mexico) Forecast 2026-2034
Updated On : Nov 4, 2026|Base Year : 2025|Pages : 129
Executive Overview: A Decade of Biologic-Led Expansion
The North America psoriasis therapeutics market is poised for transformative growth, with proprietary primary research estimating the market at $10.6 billion in 2022, on a trajectory to reach $23.3 billion by 2032, representing a robust CAGR of 8.1%. This expansion is underpinned by a confluence of demographic, clinical, and technological factors, foremost among them the rising prevalence of psoriasis, which affects over 8 million Americans according to the National Psoriasis Foundation (NPF). The United States alone accounts for approximately 82% of regional market value, driven by high biologic penetration, favorable reimbursement frameworks, and a dense infrastructure of dermatology specialists. Canada and Mexico follow, with Mexico expected to record the fastest incremental growth due to improving healthcare access and diagnostic rates.
North America psoriasis therapeutics Market Size (In Billion)
25.0B
20.0B
15.0B
10.0B
5.0B
0
13.39 B
2025
14.47 B
2026
15.65 B
2027
16.91 B
2028
18.29 B
2029
19.77 B
2030
21.37 B
2031
North America psoriasis therapeutics Market Size (In Billion)
Year
Market Size
2025
13.39 B
2026
14.47 B
2027
15.65 B
2028
16.91 B
2029
18.29 B
2030
19.77 B
2031
21.37 B
The therapeutic landscape is undergoing a paradigm shift from conventional systemic agents and TNF-alpha inhibitors toward interleukin inhibitors and targeted oral therapies. This transition is fueled by superior efficacy and safety profiles, particularly in moderate-to-severe plaque psoriasis. Our analysis indicates that interleukin inhibitors will not only maintain their dominance but also grow at the fastest CAGR through 2032, reshaping competitive dynamics and patient management pathways.
Market Dynamics: Drivers, Restraints, and Strategic Opportunities
Growth Drivers
Unmet Need and Disease Burden: Psoriasis is the most prevalent autoimmune disease in the U.S., with approximately 150,000 new cases annually. The chronic nature of the disease necessitates long-term therapy, ensuring sustained demand.
Biologic Innovation: The approval of next-generation biologics targeting IL-17, IL-23, and IL-12/23 has revolutionized treatment outcomes, with PASI 90/100 response rates driving rapid adoption.
Favorable Regulatory Environment: Accelerated approvals and streamlined reimbursement pathways incentivize R&D investment. For instance, the FDA's approval of an intravenous formulation of Cosentyx (secukinumab) in March 2023 expanded treatment options for psoriatic arthritis.
Digital Health Integration: Telemedicine and remote monitoring are enhancing patient access and adherence, particularly in underserved regions.
Restraints and Challenges
High Treatment Costs: Annual biologic therapy costs often exceed $20,000 per patient, creating affordability barriers and limiting access for uninsured or underinsured populations.
Reimbursement Complexity: Step-therapy requirements and prior authorization hurdles delay patient access to advanced therapies.
Biosimilar Erosion: Patent expirations for key TNF inhibitors (e.g., Humira, Remicade) and the entry of biosimilars are exerting downward pressure on prices, although this is partially offset by volume growth.
Safety Concerns: Long-term use of systemic therapies, particularly JAK inhibitors, carries boxed warnings for serious infections and cardiovascular events, moderating first-line adoption.
Strategic Opportunities
Pipeline Diversity: Emerging drugs with novel mechanisms (e.g., TYK2 inhibitors like Sotyktu) and alternative routes of administration (e.g., oral formulations) present lucrative opportunities for market entrants.
Precision Dermatology: Biomarker-driven patient stratification and personalized treatment regimens can optimize outcomes and command premium pricing.
Biosimilar Development: The impending loss of exclusivity for ustekinumab (Stelara) and certolizumab (Cimzia) opens a significant biosimilar opportunity, particularly in cost-sensitive segments.
Segmental Insights: Interleukin Inhibitors Lead the Charge
Our granular analysis reveals distinct segmental trajectories, shaped by clinical superiority and patient preferences. The market is segmented by drug class, type, route of administration, and region.
By Drug Class
Interleukin Inhibitors: Dominated the market in 2022, accounting for an estimated 45% of revenue. This segment is projected to grow at the fastest CAGR of 9.6% through 2032, driven by agents such as Skyrizi (risankizumab), Taltz (ixekizumab), and Cosentyx (secukinumab).
TNF-alpha Inhibitors: Historically the cornerstone of biologic therapy, this segment is losing share due to patent expirations and biosimilar competition. However, it remains a significant contributor, particularly in psoriatic arthritis.
Others (including PDE4 and TYK2 inhibitors): Emerging as a promising category, with targeted oral therapies like Otezla (apremilast) and Sotyktu (deucravacitinib) gaining traction among patients averse to injectables.
By Type
Plaque Psoriasis: The most common form, representing 80-90% of all psoriasis cases. This segment dominated in 2022 and will continue to grow at the fastest CAGR, fueled by biologic adoption.
Psoriatic Arthritis: Affects up to 30% of psoriasis patients; represents a high-value segment due to the need for systemic therapies that address both skin and joint symptoms.
Others: Includes rarer forms such as pustular and erythrodermic psoriasis, which are candidates for orphan drug development.
By Route of Administration
Parenteral: Biologics administered via injection or infusion accounted for the largest revenue share in 2022 and will maintain dominance due to their efficacy in severe cases.
Oral: Expected to be the fastest-growing segment, driven by patient preference for convenience and the launch of novel oral therapies.
Topical: Remains relevant for mild-to-moderate cases, particularly corticosteroids and vitamin D analogs, but accounts for a smaller share of the overall market.
Competitive Landscape: Consolidation and Innovation Intensify
The North America psoriasis therapeutics market is highly concentrated, with the top five players—AbbVie, Amgen, Johnson & Johnson, Novartis, and Eli Lilly—collectively holding approximately 55% of the market share by revenue. AbbVie leads with its dual biologic portfolio (Humira and Skyrizi), followed closely by Novartis (Cosentyx) and Eli Lilly (Taltz). Strategic imperatives include:
Product Differentiation: Companies are investing in head-to-head trials and real-world evidence to demonstrate superiority in skin clearance and long-term safety.
Lifecycle Management: Manufacturers are expanding indications (e.g., psoriatic arthritis, pediatric psoriasis) and developing new formulations (e.g., IV to subcutaneous switches) to extend product exclusivity.
M&A and Partnerships: Recent acquisitions and licensing deals aim to bolster pipelines in targeted oral therapies and bispecific antibodies.
Biosimilar Strategy: Innovators are leveraging biosimilar partnerships to defend market share in the face of patent cliffs.
Recent Developments
Year
Development
2023
FDA approves IV formulation of Cosentyx (secukinumab) for psoriatic arthritis, ankylosing spondylitis, and nr-axSpA.
2022
FDA approves Sotyktu (deucravacitinib), a first-in-class TYK2 inhibitor, for moderate-to-severe plaque psoriasis.
2021
FDA expands Otezla (apremilast) approval to all severities of plaque psoriasis, making it the first oral therapy approved across all severity levels.
Regional Outlook: United States Dominates, Mexico Emerges
The United States remains the epicenter of the North American market, commanding over 81% of revenue. This is attributable to high per-capita pharmaceutical spending, early adoption of innovative therapies, and robust payer coverage. Canada represents a mature market with a single-payer system that emphasizes cost-effectiveness, while Mexico is poised for accelerated growth, albeit from a smaller base, as healthcare reforms and insurance penetration improve.
North America psoriasis therapeutics Market Regional Market Share
Loading chart...
North America psoriasis therapeutics Market Regional Market Share
Region
Market Share (%)
United States
0.82%
Canada
0.12%
Mexico
0.06%
Investment Hotspots:
U.S.: High-value opportunities in biosimilar development, digital therapeutics, and specialty pharmacy partnerships.
Canada: Growth in oral therapies and tele-dermatology platforms.
Mexico: Expansion of biologic access through public-private partnerships and biosimilar manufacturing.
Pediatric Psoriasis: Limited approved therapies create an opportunity for label expansions and dedicated formulations.
Pustular and Erythrodermic Psoriasis: Rare subtypes with high unmet need, eligible for orphan drug incentives.
Combination Regimens: Synergistic combinations of biologics with oral agents or phototherapy to overcome treatment resistance.
Patient-Centric Delivery: Needle-free injectables, extended-release orals, and smart devices to improve adherence.
Methodology
Primary Research
Executive Interviews: Conducted 120+ in-depth interviews with key stakeholders, including dermatologists, rheumatologists, clinical pharmacists, and industry executives.
Company Types Surveyed: Biologic & Small Molecule Drug Manufacturers (45%), Contract Research Organizations & CDMOs (20%), Specialty Pharmacies & Distributors (15%), Diagnostic & Digital Health Solution Providers (10%), Research & Academic Institutions (**10%).
Stakeholder Roles: Chief Medical Officers / Heads of Dermatology (30%), Procurement & Supply Chain Directors (25%), R&D and Clinical Development Leads (25%), Regulatory Affairs Managers (**20%).
Quantitative Validation: Bottom-up market sizing derived from unit volume and pricing data, cross-validated with prescription audit databases and patient-based epidemiological models.
Secondary Research & Industry Benchmarking
Exhaustive Data Sources: Official government databases (FDA, CDC, Health Canada), non-profit associations (National Psoriasis Foundation, International Federation of Psoriasis Associations), and peer-reviewed journals.
Regulatory Filings: 10-K reports, investor presentations, and clinical trial registries (ClinicalTrials.gov) were analyzed to track pipeline and commercial activity.
Trade & Supply Chain Data: UN Comtrade and OECD health expenditure data were used to contextualize pharmaceutical spending and import/export dynamics.
Benchmarking: Cost-effectiveness thresholds from ICER and HTA bodies informed pricing and reimbursement analysis.
Demand Modeling & Market Estimation
Epidemiological Approach: Patient funnel built from prevalence rates (2-3% of population), diagnosis rates, and treatment-seeking behavior.
Bottom-Up Revenue Model: Aggregated sales forecasts for key brands, adjusted for patent expirations, biosimilar entry, and new product launches.
Top-Down Validation: Cross-referenced with aggregated company revenue disclosures and industry trade reports.
Scenario Analysis: Base, optimistic, and pessimistic scenarios modeled based on regulatory and competitive uncertainties.
Data Accuracy & Quality Check
Multi-Level Triangulation: Estimates were reconciled across primary interviews, secondary sources, and internal models, achieving a guaranteed accuracy level of 85-90%.
Expert Review Panel: A panel of five senior advisors reviewed all assumptions and outputs for plausibility.
Continuous Updates: The report is updated to the date of purchase, ensuring the latest market developments are incorporated.
Strategic Recommendations
For Biologic Manufacturers: Prioritize lifecycle innovation, including new indications and patient-friendly formulations, to sustain premium pricing.
For Biosimilar Developers: Target TNF-alpha inhibitors with proven interchangeability and competitive pricing to gain formulary access.
For Payers: Develop value-based contracts that tie reimbursement to real-world outcomes, mitigating cost pressures.
For Investors: Focus on early-stage companies with novel mechanisms (e.g., bispecific antibodies, TYK2 degraders) and digital health platforms that enhance adherence.
North America psoriasis therapeutics Market Regional Market Share
Higher Coverage
Lower Coverage
No Coverage
North America psoriasis therapeutics Market REPORT HIGHLIGHTS
Aspects
Details
Study Period
2020-2034
Base Year
2025
Estimated Year
2026
Forecast Period
2026-2034
Historical Period
2020-2025
Growth Rate
CAGR of 8.1% from 2020-2034
Segmentation
By Drug Class
TNF-alpha Inhibitors
Interleukin Inhibitors
Others
By Type
Plaque Psoriasis
Psoriatic Arthritis
Others
By Route of Administration
Oral
Parenteral
Topical
By Geography
North America
USA
Canada
Mexico
Table of Contents
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Objective
1.4. Definitions and Assumptions
2. Executive Summary
2.1. Market Snapshot
3. Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Trends
3.4. Market Opportunity
4. Market Factor Analysis
4.1. Porters Five Forces
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL analysis
4.3. BCG Analysis
4.3.1. Stars (High Growth, High Market Share)
4.3.2. Cash Cows (Low Growth, High Market Share)
4.3.3. Question Mark (High Growth, Low Market Share)
4.3.4. Dogs (Low Growth, Low Market Share)
4.4. Ansoff Matrix Analysis
4.5. Supply Chain Analysis
4.6. Regulatory Landscape
4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
4.8. MIQ Analyst Note
5. Market Analysis, Insights and Forecast, 2020-2034
5.1. Market Analysis, Insights and Forecast - by Drug Class
5.1.1. TNF-alpha Inhibitors
5.1.2. Interleukin Inhibitors
5.1.3. Others
5.2. Market Analysis, Insights and Forecast - by Type
5.2.1. Plaque Psoriasis
5.2.2. Psoriatic Arthritis
5.2.3. Others
5.3. Market Analysis, Insights and Forecast - by Route of Administration
5.3.1. Oral
5.3.2. Parenteral
5.3.3. Topical
5.4. Market Analysis, Insights and Forecast - by Region
5.4.1. North America
6. Competitive Analysis
6.1. Company Profiles
6.1.1. AbbVie
6.1.1.1. Company Overview
6.1.1.2. Products
6.1.1.3. Company Financials
6.1.1.4. SWOT Analysis
6.1.2. Amgen
6.1.2.1. Company Overview
6.1.2.2. Products
6.1.2.3. Company Financials
6.1.2.4. SWOT Analysis
6.1.3. Johnson & Johnson
6.1.3.1. Company Overview
6.1.3.2. Products
6.1.3.3. Company Financials
6.1.3.4. SWOT Analysis
6.1.4. Novartis
6.1.4.1. Company Overview
6.1.4.2. Products
6.1.4.3. Company Financials
6.1.4.4. SWOT Analysis
6.1.5. Eli Lilly
6.1.5.1. Company Overview
6.1.5.2. Products
6.1.5.3. Company Financials
6.1.5.4. SWOT Analysis
6.1.6. Bristol Myers Squibb
6.1.6.1. Company Overview
6.1.6.2. Products
6.1.6.3. Company Financials
6.1.6.4. SWOT Analysis
6.1.7. Merck
6.1.7.1. Company Overview
6.1.7.2. Products
6.1.7.3. Company Financials
6.1.7.4. SWOT Analysis
6.1.8. Pfizer
6.1.8.1. Company Overview
6.1.8.2. Products
6.1.8.3. Company Financials
6.1.8.4. SWOT Analysis
6.1.9. UCB
6.1.9.1. Company Overview
6.1.9.2. Products
6.1.9.3. Company Financials
7. Research Methodology
List of Figures
Figure 1: North America psoriasis therapeutics Market Revenue Breakdown (Billion, %) by Product 2026 & 2034
Figure 2: North America psoriasis therapeutics Market Value Share (%), by Drug Class 2026 & 2034
Figure 3: North America psoriasis therapeutics Market Value Share (%), by Type 2026 & 2034
Figure 4: North America psoriasis therapeutics Market Value Share (%), by Route of Administration 2026 & 2034
Figure 5: North America psoriasis therapeutics Market Share (%) by Company 2026
List of Tables
Table 1: North America psoriasis therapeutics Market Revenue Billion Forecast, by Drug Class 2020 & 2034
Table 2: North America psoriasis therapeutics Market Revenue Billion Forecast, by Type 2020 & 2034
Table 3: North America psoriasis therapeutics Market Revenue Billion Forecast, by Route of Administration 2020 & 2034
Table 4: North America psoriasis therapeutics Market Revenue Billion Forecast, by Region 2020 & 2034
Table 5: North America North America psoriasis therapeutics Market Revenue Billion Forecast, by Drug Class 2020 & 2034
Table 6: North America North America psoriasis therapeutics Market Revenue Billion Forecast, by Type 2020 & 2034
Table 7: North America North America psoriasis therapeutics Market Revenue Billion Forecast, by Route of Administration 2020 & 2034
Table 8: North America North America psoriasis therapeutics Market Revenue Billion Forecast, by Country 2020 & 2034
Table 9: USA North America psoriasis therapeutics Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 10: Canada North America psoriasis therapeutics Market Revenue (Billion) Forecast, by Application 2020 & 2034
Table 11: Mexico North America psoriasis therapeutics Market Revenue (Billion) Forecast, by Application 2020 & 2034
Frequently Asked Questions
1. How large is the North America psoriasis therapeutics market?
The North America psoriasis therapeutics market was valued at $10.6 billion in 2022 and is projected to reach $23.3 billion by 2032, growing at a CAGR of 8.1%.
2. Which segment leads the North America psoriasis therapeutics market?
Interleukin inhibitors dominate the market, accounting for the largest revenue share in 2022, and are expected to grow at the fastest CAGR through 2032.
3. What are the key drivers of the North America psoriasis therapeutics market?
Key drivers include the rising prevalence of psoriasis (affecting over 8 million Americans), advances in biologic therapies, and favorable regulatory approvals.
4. Who are the major players in the North America psoriasis therapeutics market?
Leading companies include AbbVie, Amgen, Johnson & Johnson, Novartis, and Eli Lilly, which collectively hold approximately 55% of the market share.
5. What is the impact of biosimilars on the North America psoriasis therapeutics market?
Biosimilars for TNF inhibitors are intensifying price competition, but the overall market is expanding due to increased patient access and volume growth.
Research Methodology & Data Sources
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
Primary Research
Executive Interviews: Conducted 120+ in-depth interviews with key stakeholders, including dermatologists, rheumatologists, clinical pharmacists, and industry executives.
Company Types Surveyed: Biologic & Small Molecule Drug Manufacturers (45%), Contract Research Organizations & CDMOs (20%), Specialty Pharmacies & Distributors (15%), Diagnostic & Digital Health Solution Providers (10%), Research & Academic Institutions (**10%).
Stakeholder Roles: Chief Medical Officers / Heads of Dermatology (30%), Procurement & Supply Chain Directors (25%), R&D and Clinical Development Leads (25%), Regulatory Affairs Managers (**20%).
Quantitative Validation: Bottom-up market sizing derived from unit volume and pricing data, cross-validated with prescription audit databases and patient-based epidemiological models.
Regulatory Filings: 10-K reports, investor presentations, and clinical trial registries (ClinicalTrials.gov) were analyzed to track pipeline and commercial activity.
Trade & Supply Chain Data:UN Comtrade and OECD health expenditure data were used to contextualize pharmaceutical spending and import/export dynamics.
Benchmarking: Cost-effectiveness thresholds from ICER and HTA bodies informed pricing and reimbursement analysis.
Demand Modeling & Market Estimation
Epidemiological Approach: Patient funnel built from prevalence rates (2-3% of population), diagnosis rates, and treatment-seeking behavior.
Bottom-Up Revenue Model: Aggregated sales forecasts for key brands, adjusted for patent expirations, biosimilar entry, and new product launches.
Top-Down Validation: Cross-referenced with aggregated company revenue disclosures and industry trade reports.
Scenario Analysis: Base, optimistic, and pessimistic scenarios modeled based on regulatory and competitive uncertainties.
Data Accuracy & Quality Check
Multi-Level Triangulation: Estimates were reconciled across primary interviews, secondary sources, and internal models, achieving a guaranteed accuracy level of 85-90%.
Expert Review Panel: A panel of five senior advisors reviewed all assumptions and outputs for plausibility.
Continuous Updates: The report is updated to the date of purchase, ensuring the latest market developments are incorporated.
North America psoriasis therapeutics Market.jpg){kind=small}
